

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

**POLL RESULTS OF EXTRAORDINARY GENERAL MEETING
HELD ON 27 DECEMBER 2023**

Poll Results of EGM

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of extraordinary general meeting (the “**EGM**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) both dated 5 December 2023. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular and the Notice.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the EGM was held at 10:30 a.m. on Wednesday, 27 December 2023 at Room 1405–1409, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong and the proposed ordinary resolutions set out in the Notice were duly passed at the EGM. All Directors attended the EGM.

As at the date of the EGM, there were 837,100,000 shares (the “**Share(s)**”) of the Company in issue. As disclosed in the Circular, Tong Ren Tang Holdings and its associates, directly and indirectly holding in an aggregate of 600,000,000 Shares, representing approximately 71.67% of the issued share capital of the Company, have material interests in the proposed transactions under the resolutions considered at the EGM and therefore Tong Ren Tang Holdings and its associates have abstained from voting on such resolutions at the EGM.

Save as disclosed above, as at the date of the EGM, (i) no shareholder of the Company (the “**Shareholder(s)**”) was required to abstain from voting on the resolutions proposed at the EGM under the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”); (ii) there was no Share entitling the holders to attend and abstain from voting in favour of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (iii) there was no Share entitling the holders to attend and vote only against the resolutions proposed at the EGM; and (iv) none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM. Accordingly, a total of 237,100,000 Shares was the total number of Shares entitling the holders to attend and vote for or

against the resolutions proposed at the EGM. The Shareholders and authorized proxies holding an aggregate of 58,128,497 Shares carrying voting rights voted at the EGM.

The poll results are as follows:

As Ordinary Resolutions	Number of votes cast (percentage of total number of votes cast, %)	
	For	Against
<p>1. THAT, the new exclusive distributorship framework agreement entered into by the Company with Tong Ren Tang Technologies Co. Ltd. on 29 November 2023 (the “New TRT Tech Exclusive Distributorship Framework Agreement”), and the new annual caps for the three years ending 31 December 2026 for the continuing connected transactions of the Company contemplated under the New TRT Tech Exclusive Distributorship Framework Agreement are hereby approved, ratified and confirmed; and THAT any one director of the Company be and is hereby authorized to sign or execute such other documents or supplemental agreements or deeds on behalf of the Company and to do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the terms of the New TRT Tech Exclusive Distributorship Framework Agreement and completing the transactions contemplated thereunder with such changes as he may consider necessary, desirable or expedient.</p>	<p>58,128,485 99.999979%</p>	<p>12 0.000021%</p>
<p>2. THAT, the new exclusive distributorship framework agreement entered into by the Company with Beijing Tong Ren Tang Company Limited on 29 November 2023 (the “New TRT Ltd. Exclusive Distributorship Framework Agreement”), and the new annual caps for the three years ending 31 December 2026 for the continuing connected transactions of the Company contemplated under the New TRT Ltd. Exclusive Distributorship Framework Agreement are hereby approved, ratified and confirmed; and THAT any one director of the Company be and is hereby authorized to sign or execute such other documents or supplemental agreements or deeds on behalf of the Company and to do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the terms of the New TRT Ltd. Exclusive Distributorship Framework Agreement and completing the transactions contemplated thereunder with such changes as he may consider necessary, desirable or expedient.</p>	<p>58,128,485 99.999979%</p>	<p>12 0.000021%</p>

As more than 50% of the total valid voting rights held by attending Shareholders and authorized proxies were cast in favour of resolutions, the ordinary resolutions as set out in the Notice were duly passed by way of poll as ordinary resolutions.

According to the requirements of the Listing Rules, Computershare Hong Kong Investor Services Limited, the Company's share registrar, was appointed scrutineer in respect of vote-taking at the EGM.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Gu Hai Ou
Chairman

Hong Kong, 27 December 2023

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Mr. Gu Hai Ou (*Chairman*)
Mr. Yu Jin
Mr. Chen Fei

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li